Batia R. Avni

Jerusalem, JM, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real-World Study.

Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real-World Study.

Journal: Hematological oncology

Published: March 23, 2026

B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis.

B cell Maturation Antigen Targeted Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus and Systemic Sclerosis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: March 11, 2026

Touch DNA is predominantly transferred from leukocytes, not skin cells.

Touch DNA is predominantly transferred from leukocytes, not skin cells.

Journal: Forensic science international. Genetics

Published: February 13, 2026

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.

Journal: International journal of molecular sciences

Published: January 20, 2026

High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T).

High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T).

Journal: Cancers

Published: September 21, 2025

CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia.

CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia.

Journal: Journal of cellular and molecular medicine

Published: March 29, 2025

Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.

Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 09, 2024

Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study.

Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study.

Journal: Bone marrow transplantation

Published: December 03, 2024

Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin.

Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin.

Journal: Frontiers in immunology

Published: November 11, 2024

MIF functional polymorphisms are associated with acute GVHD progression and steroid-refractoriness.

MIF functional polymorphisms are associated with acute GVHD progression and steroid-refractoriness.

Journal: Frontiers in immunology

Published: October 01, 2024

Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients - A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts.

Endothelial Activation and Stress Index Score as a Prognostic Factor of Cytokine Release Syndrome in CAR-T Patients - A Retrospective Analysis of Multiple Myeloma and Large B-Cell Lymphoma Cohorts.

Journal: Archivum immunologiae et therapiae experimentalis

Published: May 18, 2024

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.

Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.

Journal: Blood advances

Published: February 20, 2024

Showing 1-12 of 61

Last Updated: 09/26/2026